Back to Results
First PageMeta Content
Medicine / Apoptosis / Programmed cell death / Tumor suppressor genes / P53 / Mdm2 / Neuroblastoma / Nutlin / Ataxia telangiectasia mutated / Biology / Proteins / Cell biology


Pediatric Subcommittee of the Oncologic Drugs Advisory Committee The MDM2 antagonist RO5503781 Gwen L Nichols MD Translational Medicine Oncology Roche Pharmaceutical Research and Early Development
Add to Reading List

Open Document

File Size: 2,68 MB

Share Result on Facebook

Company

NCH / /

Country

France / Netherlands / Italy / Canada / Australia / United Kingdom / South Korea / /

Event

FDA Phase / /

Facility

Baylor College of Medicine / /

IndustryTerm

food effect / chemical class / /

MedicalCondition

Colon cancer MDM2 / tumor / cancer / multiple myeloma / Best response stable disease / adult cancer / agent treatment RH18 Rhabdomyosarcoma / solid tumor / Solid Tumors / Ewing's sarcoma / neuroblastoma / metastatic castration-resistant prostate cancer / pediatric tumor / myeloproliferative neoplasms / sarcomas / Medulloblastoma / NGP mice Tumor Weights RG7388 / I Solid Tumors / Rhabdomyosarcoma / /

MedicalTreatment

radiation / /

Organization

Baylor College of Medicine / Houston / E. DeBakey Department of Surgery / Suitable administration / European Medicines Agency / Baylor College of Medicine / U.S. Food and Drug Administration / Texas Children’s Cancer Center / Department of Pediatrics / Division of Pediatric Surgery / Pediatric Subcommittee / /

Person

John Lunec / Peter Houghton / David R. Newell / Gwen L Nichols / /

Product

cytarabine / Solid Tumors / NP27872 / NP28679 / RO5503781 / /

Technology

radiation / Apoptosis / /

SocialTag